POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
Atari® Reveals Sunnyvale, A Massive New Experience in The Sandbox
September 09, 2022 13:00 ET
|
Atari Inc.
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atari® — one of the world's most iconic consumer brands and interactive entertainment producers — today announced the launch of Atari Sunnyvale, a...
The Jimmy Fund Let’s Game “Quest 2 Defy Cancer” Fundraising Initiative Kicks Off Today, Calling Upon Gaming Influencers to Rally for the Cause
September 01, 2022 09:45 ET
|
Dana-Farber Cancer Institute
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Dana-Farber Cancer Institute — the foremost comprehensive cancer research and treatment facility in the United States — announced today the formal kick-off...
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
August 08, 2022 08:30 ET
|
POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
TOP RANKED ROSEN LAW FIRM Encourages Allianz SE Investors with Losses to Inquire About Class Action Investigation – ALIZY
June 09, 2022 17:21 ET
|
The Rosen Law Firm PA
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allianz SE (OTC:...
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
May 13, 2022 08:30 ET
|
POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET
|
POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET
|
POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
April 11, 2022 16:30 ET
|
POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
Draganfly CEO Cameron Chell to be Featured on CTV “Your Morning”
March 28, 2022 06:30 ET
|
Draganfly Inc
Los Angeles, CA., March 28, 2022 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and...